Next Article in Journal
Developments in Viral Vector-Based Vaccines
Next Article in Special Issue
Schistosome Vaccine Adjuvants in Preclinical and Clinical Research
Previous Article in Journal
Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8+ T Cell Epitopes
Previous Article in Special Issue
Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification
Article Menu

Export Article

Open AccessArticle
Vaccines 2014, 2(3), 601-623; doi:10.3390/vaccines2030601

Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation

1
Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Universität Leipzig, Deutscher Platz 5, Leipzig 04103, Germany
2
Center for Biotechnology and Biomedicine (BBZ), Universität Leipzig, Deutscher Platz 5, Leipzig 04103, Germany
3
Rudolf Boehm Institute for Pharmacology and Toxicology, Universität Leipzig, Leipzig 04107, Germany
*
Author to whom correspondence should be addressed.
Received: 31 March 2014 / Revised: 11 June 2014 / Accepted: 11 June 2014 / Published: 29 July 2014
(This article belongs to the Special Issue Peptide Vaccine)
View Full-Text   |   Download PDF [995 KB, uploaded 29 July 2014]   |  

Abstract

Intracellular neurofibrillary tangles and extracellular senile plaques are potential targets for active and passive immunotherapies. In this study we used the transgenic mouse model P301S for active immunizations with peptide vaccines composed of a double phosphorylated tau neoepitope (pSer202/pThr205, pThr212/pSer214, pThr231/pSer235) and an immunomodulatory T cell epitope from the tetanus toxin or tuberculosis antigen Ag85B. Importantly, the designed vaccine combining Alzheimer’s disease (AD) specific B cell epitopes with foreign (bacterial) T cell epitopes induced fast immune responses with high IgG1 titers after prophylactic immunization that subsequently decreased over the observation period. The effectiveness of the immunization was surveyed by evaluating the animal behavior, as well as the pathology in the brain by biochemical and histochemical techniques. Immunized mice clearly lived longer with reduced paralysis than placebo-treated mice. Additionally, they performed significantly better in rotarod and beam walk tests at the age of 20 weeks, indicating that the disease development was slowed down. Forty-eight weeks old vaccinated mice passed the beam walk test significantly better than control animals, which together with the increased survival rates undoubtedly prove the treatment effect. In conclusion, the data provide strong evidence that active immune therapies can reduce toxic effects of deposits formed in AD. View Full-Text
Keywords: Alzheimer’s disease; immunization; peptide vaccine; phospho-tau; transgenic mouse model; P301S mice Alzheimer’s disease; immunization; peptide vaccine; phospho-tau; transgenic mouse model; P301S mice
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Richter, M.; Mewes, A.; Fritsch, M.; Krügel, U.; Hoffmann, R.; Singer, D. Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation. Vaccines 2014, 2, 601-623.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top